Regulator of telomere length 1 (
Adult
Aged
Aged, 80 and over
DNA Helicases
/ genetics
Exome
Female
Follow-Up Studies
Gene Expression Regulation
Heterozygote
Humans
Lung Diseases
/ genetics
Lung Diseases, Interstitial
/ genetics
Male
Middle Aged
Mutation
Pedigree
Phenotype
Sequence Analysis, DNA
Telomerase
/ genetics
Vital Capacity
Journal
The European respiratory journal
ISSN: 1399-3003
Titre abrégé: Eur Respir J
Pays: England
ID NLM: 8803460
Informations de publication
Date de publication:
02 2019
02 2019
Historique:
received:
13
03
2018
accepted:
06
11
2018
pubmed:
14
12
2018
medline:
31
10
2020
entrez:
8
12
2018
Statut:
epublish
Résumé
Regulator of telomere length 1 (
Identifiants
pubmed: 30523160
pii: 13993003.00508-2018
doi: 10.1183/13993003.00508-2018
pii:
doi:
Substances chimiques
TERT protein, human
EC 2.7.7.49
Telomerase
EC 2.7.7.49
RTEL1 protein, human
EC 3.6.1.-
DNA Helicases
EC 3.6.4.-
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright ©ERS 2019.
Déclaration de conflit d'intérêts
Conflict of interest: R. Borie reports grants and personal fees from Roche, personal fees from Boerhinger Ingelheim and Savapharma, outside the submitted work. Conflict of interest: D. Bouvry has nothing to disclose. Conflict of interest: V. Cottin reports personal fees for consultancy, lecturing and travel to medical meetings from Actelion and Roche, personal fees for development of educational presentations, consultancy, lecturing and travel to medical meetings from Boehringer Ingelheim, personal fees for consultancy from Bayer and GSK, personal fees for adjudication committee work from Gilead, personal fees for consultancy and travel to medical meetings from MSD, personal fees for consultancy and lecturing from Novartis and Sanofi, institutional grants from Boehringer Ingelheim and Roche, personal fees for data and safety monitoring board work from Promedior and Celgene, personal fees for consultancy and data and safety monitoring board work from Galapagos, outside the submitted work. Conflict of interest: C. Gauvain has nothing to disclose. Conflict of interest: A. Cazes has nothing to disclose. Conflict of interest: M-P. Debray reports personal fees from Boehringer-Ingelheim, and reimbursement for travel and accommodation for medical meeting for Guerbet and Roche, outside the submitted work. Conflict of interest: J. Cadranel has nothing to disclose. Conflict of interest: P. Dieude has nothing to disclose. Conflict of interest: T. Degot reports personal fees for expert testimony in ILD and travel reimbursement for the Congress CPLF 2018 in Lyon from Boerhinger Ingelheim France, and personal fees for expert testimony in ILD from Roche France, outside the submitted work. Conflict of interest: S. Dominique reports personal fees from Roche and Boehringer Ingelheim, outside the submitted work. Conflict of interest: A.S. Gamez has nothing to disclose. Conflict of interest: M. Jaillet has nothing to disclose. Conflict of interest: P-A. Juge has nothing to disclose. Conflict of interest: A. Londono-Vallejo has nothing to disclose. Conflict of interest: A. Mailleux has nothing to disclose. Conflict of interest: H. Mal has nothing to disclose. Conflict of interest: C. Boileau has nothing to disclose. Conflict of interest: C. Menard has nothing to disclose. Conflict of interest: H. Nunes has nothing to disclose. Conflict of interest: G. Prevot has nothing to disclose. Conflict of interest: S. Quetant has nothing to disclose. Conflict of interest: P. Revy has nothing to disclose. Conflict of interest: J. Traclet has nothing to disclose. Conflict of interest: L. Wemeau-Stervinou reports personal fees and non-financial support from Boehringer-Ingelheim and Roche, personal fees from Bristol-Myers-Squibb and Jansen-Cilag, outside the submitted work. Conflict of interest: M. Wislez has nothing to disclose. Conflict of interest: C. Kannengiesser has nothing to disclose. Conflict of interest: B. Crestani reports grants for research and personal fees for development of educational presentations, consultancy, lecturing and travel to medical meetings from Boehringer Ingelheim, grants for research and personal fees for consultancy, lecturing and travel to medical meetings from Roche, personal fees for consultancy and lecturing from Sanofi and Apellis, personal fees for consultancy, lecturing and travel to medical meetings from AstraZeneca, and research grants from MedImmune, outside the submitted work.